More than 2 years since the original trial data for lecanemab in Alzheimer's disease was published,1 and over 1·5 years since approval by the US Food and Drug Administration, brain volume data have ...
Laboratory of Precision Nanomedicine, Shmunis School of Biomedicine and Cancer Research, Tel Aviv University, Tel Aviv-Yafo 69978, Israel Department of Materials Sciences and Engineering, Tel Aviv ...
By offering a clearer picture of the microbial underpinnings of NAFLD, this research paves the way for microbiome-based diagnostic tools and personalised treatment approaches. The discovery of these ...
Alcohol harms your liver. Talk to your doctor. They may refer you to a treatment program. MASLD (formerly called nonalcoholic fatty liver disease). Type 2 diabetes, metabolic syndrome, and obesity ...
Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, Atlanta, Georgia 30332, United States School of Electrical & Computer ...
Conclusions Non-pharmacological therapies of depression reduce depression symptoms and should be considered along with antidepressant therapy for the treatment of mild-to ... reviews by screening ...
Methods Sedentary adults with clinically defined NAFLD were assigned to 8 weeks of resistance exercise (n=11) or continued normal treatment (n=8). Results 8 weeks of resistance exercise elicited a 13% ...
Objective Non-alcoholic fatty liver disease (NAFLD) is a major public health burden ... 95% CI 1.888 to 5.850), blood pressure ≥140/90 mm Hg or antihypertensive drug treatment (OR 1.451, 95% CI 1.069 ...
Request permissions for this article. Department of Neurology, Sun Yat-Sen Memorial HospitalSun Yat-sen University Guangzhou 510120 China Brain Research Center, Sun Yat-sen Memorial HospitalSun ...
Overactive bladder (OAB) affects 11-17% of the female population. First-line treatment with lifestyle modifications and second-line therapy with medications are often limited by inadequate efficacy or ...
This systematic review, registered on the Prospective Register of Systematic Reviews (RD42024528812), investigated whether home-based ES would be as viable as outpatient ES in the treatment of women ...
Zevra Therapeutics, Inc. announced that it will receive a 2025 New Treatment Award for its product MIPLYFFAâ„¢ (arimoclomol) at the 21st Annual WORLDSymposium. Eight abstracts related to MIPLYFFA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback